21
Participants
Start Date
November 30, 2006
Primary Completion Date
December 31, 2006
Study Completion Date
February 28, 2009
VEGFR2-169 and gemcitabine
Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
Wakayama Medical University Hospital, 811-1 Kimiidera, Wakayama
Human Genome Center, Institute of Medical Science, University of Tokyo
OTHER
Wakayama Medical University
OTHER